Investigation into the Delayed Reporting of a Drug Failure Study
-
Dr. McMillan discusses delayed reporting of a drug study without naming specifics. • 0:01
-
Previous experience with restrictions on discussing companies leads to cautious approach. • 0:38
-
Upcoming projects include a disease X book compilation and a book launch for Humming Heroes. • 1:44
-
Advanced360 pre-launch sale offers significant discounts for upcoming course modules. • 3:33
Delay in reporting failure of Paxlovid efficacy in treating COVID-19 raises questions about scientific community's awareness
-
Publication of Paxlovid failure delayed for almost two years after initial study showed benefit. • 3:56
-
Recent study in April 2024 concluded no significant difference in efficacy between Paxlovid and placebo. • 5:30
-
CDC still recommends Paxlovid despite lack of proven effectiveness against COVID-19. • 6:43
-
Lack of effective antiviral treatment accepted by scientific community to stop COVID-19. • 7:16
-
Question raised on why it took so long to report the failure of Paxlovid. • 7:22
-
Significance of delayed publication in understanding the evolving landscape of COVID-19 treatments. • 7:45
-
Challenges in reconciling conflicting study results and implications for future research and treatment strategies. • 8:04
Delay in publishing negative results of Paxlovid study raises questions about timing and impact
-
Study completed in December 2021, published in February 2022, showing quick turnaround potential. • 8:17
-
Another study completed in July 2022 but published in April 2024, raising concerns about the delay. • 9:31
-
Significant delay of almost 2 years between study completion and publication without clear reasons. • 10:33
-
Data on adverse events and lack of significant benefits from Paxlovid treatment highlighted in the study. • 12:17
-
Questions raised on the impact of delayed publication on sales and public perception of the medication. • 13:05
Factors contributing to the lack of efficacy of an antiviral drug in vaccinated individuals
-
Initial trial showed benefit in unvaccinated cohort but not in mixed cohort. • 13:54
-
Possible impact of natural immunity in unvaccinated cohort on trial outcome. • 14:51
-
Antiviral drug targets specific protease enzymes of the Coronavirus. • 15:47
-
Speculation on immune failure and presence of immune-tolerant antibodies in vaccinated individuals. • 16:09
-
Suggested need for longer treatment duration in vaccinated individuals due to potential immune deficiency. • 17:03
-
Drug slows down viral replication process, while immune system clears infected cells. • 17:41
Concerns raised about immune system failure, need for new leadership to address challenges in protecting at-risk individuals from severe disease
-
Combination of immunity and viral proteins slowing virus down • 17:57
-
Issues around finance and immune failure in cohort • 18:14
-
Science indicating serious challenge ahead, need to stop virus circulation • 18:56
-
Main organizations promoting pharmaceutical therapies facing limitations • 19:04
-
Urgent need to protect at-risk individuals from severe disease • 19:42
-
Call for new leadership to address current crisis • 20:00
-
Concern about big pharma taking advantage of situation, need for protection • 20:22